Exosome Diagnostics Enters Agreement with Amgen
Exosome Diagnostics, Inc. has entered into an agreement with Amgen to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform.
(firmenpresse) - Cambridge, MA, October 06, 2016 -- Exosome Diagnostics, Inc. has entered into an agreement with Amgen to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform. Under the terms of the agreement, the companies will collaborate to identify a potential liquid biopsy diagnostic. Financial terms of the agreement were not disclosed.
Liquid biopsies are effective in advancing therapeutics because of their distinct advantage over tissue biopsies. A significant advantage is that they are less invasive, resulting in fewer complications and risks to the patient during sample collection. Liquid biopsies enable easier sample collection and may help facilitate patient enrollment into trials.
“We are excited to initiate this agreement with Amgen on developing technology that may advance the use of liquid biopsy tests in clinical development,” stated Mario Morken, Head of Business Development for Exosome Diagnostics. “Exosome Diagnostic’s technology and expertise allows for the development of highly sensitive liquid biopsy assays.”
“The strategy and positioning of the company since the beginning of 2016 is garnering significant results, and we look forward to expounding upon these successes,” stated John Boyce, President and CEO of Exosome Diagnostics.
About Exosome Diagnostics:
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.
ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.
Company / Media Contact:
Dan Baughman
Exosome Diagnostics
dbaughman(at)exosomedx.com
248-613-2247
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2016 - 10:56 Uhr
Sprache: Deutsch
News-ID 1462462
Anzahl Zeichen: 2384
contact information:
Contact person: Dan Baughman
Town:
Cambridge
Phone: 2486132247
Kategorie:
Medical Devices
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Exosome Diagnostics Enters Agreement with Amgen
"
steht unter der journalistisch-redaktionellen Verantwortung von
Exosome Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
